5-MeO-AMT

Discovery

5-MeO-AMT was first synthesized in the late 1950s, with some sources citing approximately 1958.^[4] Its psychoactive properties remained undocumented until 1978, when Alexander Shulgin and David Nichols published the first characterization of its psychedelic effects in humans.^[4] Shulgin later included the compound in TiHKAL (1997) under the designation α,O-DMS, reporting an oral dose range of 2.5–4.5 mg and a duration of 12–18 hours.^[1]

Market emergence and misidentification

5-MeO-AMT appeared on research chemical markets around 2000–2002 as pressed tablets sold under the name "Alpha-O," coinciding with a major disruption of global LSD supply.^[5][4] The compound was sometimes misrepresented as LSD on blotter or in liquid form — a dangerous substitution, since 5-MeO-AMT is active at milligram doses with a narrow safety margin, while LSD is active at microgram doses with a wide one.^[8] Further confusion arose from its similarity to AMT, which has a much higher active dose range (15–50 mg); a user receiving 5-MeO-AMT believing it to be AMT risked consuming a drastically excessive amount.^[7][5]

Regulatory history

The DEA proposed placing 5-MeO-AMT in Schedule I in January 2022, citing reports of agitation, psychological distress, and death.^[10] In an unusual reversal, the agency withdrew the proposal six months later without publicly detailing its reasons.^[6] As of 2026, 5-MeO-AMT remains federally unscheduled in the United States, though it is controlled in the United Kingdom (Class A), Australia (Schedule 9), and Sweden.

Structural class

5-MeO-AMT belongs to the substituted tryptamine family, sharing the indole scaffold common to serotonin, DMT, psilocin, and 5-MeO-DMT. The compound can be understood as the α-methyl structural analog of 5-MeO-DMT or the 5-methoxy analogue of α-methyltryptamine. The α-methyl group on the ethylamine side chain — the same modification that distinguishes amphetamine from phenylethylamine — confers resistance to monoamine oxidase degradation, enabling oral activity and contributing to the compound's extended duration.^[1]

Molecular properties

The molecule consists of a bicyclic indole ring system with a methoxy group at position 5 and a 2-aminopropyl side chain at position 3.^[11]

Stereochemistry

The α-methyl group creates a chirality centre, and 5-MeO-AMT exists as (R)- and (S)-enantiomers. No published data characterize the psychoactive potency or receptor selectivity of individual enantiomers. Research and community use is typically racemic mixture. citation needed

Physical properties

No published characterization of salt forms or water solubility data for the freebase was located.^[8]

Mechanism of action

5-MeO-AMT produces its psychedelic effects primarily through activation of the 5-HT₂A receptor. In rodent studies, the compound elicits dose-dependent head-twitch responses — the standard proxy for hallucinogenic activity — and this response is fully blocked by selective 5-HT₂A antagonists, confirming 5-HT₂A as the primary mediator.^[9][12]

What sets 5-MeO-AMT apart from most serotonergic psychedelics is its additional action on monoamine transporters. The compound inhibits reuptake and induces release of serotonin, dopamine, and norepinephrine — a mixed inhibitor/releaser profile similar to αMT but uncommon among psychedelics.^[2][3] This dual identity underlies the compound's stimulant-like qualities alongside its psychedelic effects.

In drug discrimination studies, 5-MeO-AMT produced partial substitution for LSD but did not fully substitute for DMT, DOM, LSD, cocaine, or methamphetamine.^[13] The compound occupies pharmacological space between classical psychedelics and monoamine releasers without cleanly fitting either category.

Pharmacokinetics

No controlled pharmacokinetic studies have been published in humans. Key parameters — time to peak concentration, oral bioavailability, plasma half-life, and protein binding — remain uncharacterized.

The prolonged duration of action (12–18 hours orally) is consistent with the α-methyl group's resistance to monoamine oxidase degradation, which slows metabolism relative to non-α-methylated tryptamines like 5-MeO-DMT. Rat studies have confirmed a complex urinary metabolite profile,^[14] and by analogy with structurally related compounds, the expected metabolic pathways include O-demethylation and aromatic hydroxylation.^[15]

Monoamine oxidase A is the expected primary catabolic enzyme. This is the mechanistic basis for the critical interaction with MAO inhibitors: blocking this pathway would dramatically increase systemic exposure and prolong an already extended duration.

Where it acts

As a potent serotonin 2A receptor agonist, 5-MeO-AMT is expected to activate the same cortical circuits disrupted by other serotonergic psychedelics: layer V pyramidal neurons in the prefrontal cortex, thalamocortical gating systems, and the default mode network.^[3] Preclinical studies confirm direct molecular engagement — the compound increases 5-HT₂A gene expression in the prefrontal cortex and activates downstream signalling cascades associated with neuroplasticity.^[9]

Neurochemistry studies in rats show that 5-MeO-AMT simultaneously affects dopamine and serotonin levels across the prefrontal cortex, nucleus accumbens, striatum, and hippocampus.^[16] This broader engagement pattern — spanning reward, executive, motor, and memory circuits — distinguishes it from pure serotonergic psychedelics like psilocin.

Why it matters

5-MeO-AMT activates intracellular signalling pathways that overlap with those implicated in psychedelic-induced structural neuroplasticity — the growth of new neural connections.^[9] Whether the compound actually promotes these changes at relevant concentrations has not been tested directly.

Despite measurable dopamine release in reward-relevant brain regions, 5-MeO-AMT does not produce self-administration, conditioned place preference, or locomotor sensitization in rodents.^[9][16] This dissociation — dopamine release without behavioural reinforcement — is consistent with the broader pattern for serotonergic psychedelics, where concurrent 5-HT₂A activation appears to attenuate the rewarding properties of dopamine.

Toxicity

The compound has a narrow margin between active and dangerous doses. Shulgin reported an active oral dose range of 2.5–4.5 mg,^[1] with overdose symptoms reported at doses as low as 20 mg — roughly 4–10 times the common range.^[7][8] This is substantially narrower than LSD or psilocybin.

Overdose presents as a sympathomimetic toxidrome: rapid heart rate, high blood pressure, seizures, dangerously elevated body temperature, and cardiac rhythm disturbances.^[17]

Multiple hospitalizations have resulted from misidentification of 5-MeO-AMT as αMT or LSD. A user consuming 15–50 mg believing the substance to be AMT would receive 3–20 times the upper active dose range.^[7][5]

Psychological risks

5-MeO-AMT can precipitate panic reactions, severe anxiety, confusion, and terrifying hallucinations — the latter specifically noted at higher doses.^[5] The compound's extended duration means adverse psychological experiences persist far longer than with shorter-acting psychedelics, with limited options for intervention beyond supportive care and benzodiazepine sedation.

No data on HPPD incidence specific to 5-MeO-AMT have been published. Family history of psychotic spectrum disorders constitutes a risk factor for psychedelic-triggered psychosis — a class-level concern for all serotonin 2A receptor agonists.^[7]

Tolerance and dependence

Tolerance develops through downregulation. Repeated administration over 7 days in mice reduced the head-twitch response while increasing 5-HT₂A gene expression in the prefrontal cortex — a compensatory transcriptional change consistent with receptor desensitization.^[9] Cross-tolerance with other 5-HT₂A psychedelics (LSD, psilocybin, mescaline) is expected based on this shared mechanism.^[20]

5-MeO-AMT does not produce physical dependence. Rodent studies found no conditioned place preference and no self-administration, indicating low reinforcement potential.^[9] No human data on dependence, withdrawal, or addiction exist.

Drug interactions

No published drug-drug interaction studies exist for 5-MeO-AMT. All interaction data relies on pharmacological extrapolation.

Contraindications

The following contraindications are based on pharmacological mechanism and class-level evidence. No substance-specific contraindication studies have been published.

Absolute contraindications:

• Concurrent MAOI use — risk of fatal serotonin syndrome^[7]
• Seizure disorders — the compound lowers seizure threshold at excessive doses^[7][17]
• Heart rhythm disorders or structural heart disease — combined sympathomimetic effects and potent 5-HT₂B activation create dual cardiovascular risk^[3]

Relative contraindications:

• Personal or family history of psychotic spectrum disorders — risk of psychedelic-triggered psychosis^[7]
• Concurrent SSRI or SNRI use — serotonin syndrome risk^[21]
• Concurrent lithium use — unpredictable potentiation and seizure risk inferred
• Liver impairment — expected impairment of metabolism could increase blood levels inferred
• Pregnancy and lactation — no reproductive toxicity data exist; contraindicated by precautionary principle

5-MeO-AMT occupies an unusual legal position among serotonergic tryptamines. It remains federally unscheduled in the United States — a status preserved when the DEA withdrew its proposed Schedule I placement in July 2022.^[6] This contrasts with the structurally related αMT (Schedule I since 2003) and 5-MeO-DMT (Schedule I since 2011). In the United Kingdom and Australia, the compound is controlled under broad tryptamine scheduling provisions. Legal status varies by jurisdiction and should be verified against current legislation before any activity involving this substance.

The Federal Analogue Act (21 U.S.C. § 813) provides a potential enforcement mechanism in the United States, but its application requires demonstrating both structural similarity to a Schedule I or II substance and intent for human consumption, assessed case by case.